The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation

Transplantation

Volumn 68, Issue 9, 1999, Pages 1272-1279

  Kruger, Robert M ^a,b   Shannon, William D ^b   Arens, Max Q ^b   Lynch, John P ^b   Storch, Gregory A ^b   Trulock, Elbert P ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMOCYTE ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD CULTURE; BRONCHIOLITIS; BRONCHOSCOPY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA BASE; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS ISOLATION;

EID: 0033570920     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00010     Document Type: Article

References (36)

1. Kennan R, Lega M, Dummer J, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991; 51(2): 433.
2. Bando K, Paradis I, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation. J Thorac Cardiovasc Surg 1995; 110: 4.
3. Bando K, Paradis I, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995; 109: 49.
4. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman III RM. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195.
5. Duncan S, Paradis I, Yousem S, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992; 146: 1419.
6. Keller C, Cagle P, Brown R, Noon G, Frost A. Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest 1995; 107: 973.
7. Peterson P, HH Balfour J, Marker S, Fryd D, Howard R, Simmons R. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 1980; 59: 283.
8. Rubin R. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12 (suppl 7): S754.
9. Chatterjee S, Fiala M, Weiner J, Stewart J, Stacey B, Warmer N. Primary cytomegalovirus and opportunistic infections. JAMA 1978; 240 (22): 2446.
10. Arend S, Westendorp R, Kroon F, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1995; 22: 920.
11. Biron K, Fyfe J, Stanat S, et al. A human cytomegalovirus mutant resistant to the the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 1986; 83: 8769.
12. Erice A, Chou S, Biron K, Stanat S, HH Balfour J, Jordan M. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989; 320 (5): 289.
13. Rosen H, Benner K, Flora K, et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997; 63(3): 476.
14. Boivin G, Gilbert C, Morissette M, Handfield J, Goyette N, Bergeron M. A case of ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with AIDS: longitudinal molecular analysis of the CMV viral load and viral mutations in blood compartments. AIDS 1997; 11: 867.
15. Baldanti F, Simoncini L, Sarasini A, et al. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood. Transplantation 1998; 66(3): 324.
16. Singh N, Yu V. Oral Ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients. Dig Dis Sci 1998; 43 (6): 1190.
17. Trulock E. Lung Transplantation. Am J Respir Crit Care Med 1997; 155: 789.
18. Fishman J, Rubin R. Infection in organ-transplant recipients. N Engl J Med 1998; 338 (24): 1741.
19. Boivin G, Chou S, Quirk M, Erice A, Jordan M. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis 1996; 173: 523.
20. Jabs D, Dunn J, Enger C, Forman M, Bressler N, Charache P. Cytomegalovirus retinitis and viral resistance. Arch Ophthalmol 1996; 114: 809.
21. Slavin M, Bindra R, Gleaves C, Pettinger M, Bowden R. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 37 (6): 1360.
22. Tokumoto J, Hollander H. Cytomegalovirus polyradiculopathy caused by a ganciclovir-resistant strain. Clin Infect Dis 1993; 17: 854.
23. Drew W, Miner R, Busch D, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991; 163: 716.
24. Alain S, Honderlick P, Grenet D, et al. Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 1997; 63 (10): 1533.
25. Lurain N, Ammons H, Kapell K, Yeldandi V, Garrity E, O'Keefe J Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor. Transplantation 1996; 62: 497.
26. Boivin G, Erice A, Crane D, Dunn D, HH Balfour J Ganciclovir susceptibilities of cytomegalovirus (cmv) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993; 168: 332.
27. Lennette E. Diagnostic Procedures for viral, rickettsial and chlamydial infections, 5th ed. Washington, D.C.: American Public Health Association, 1979.
28. Yousem S, Berry G, Cagle P. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J Heart Lung Transplant 1996; 15 (1): 1.
29. Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
30. Sundaresan S, Trulock E, Mohanakumar T, Cooper J, Patterson G. Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Ann Thorac Surg 1995; 60: 1341.
31. Cooper J, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12 (5): 713.
32. Yousem S, Berry G, Brunt E, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: lung rejection study group. J Heart Transplant 1990; 9 (6): 593.
33. Balfour H. Cytomegalovirus. The troll of transplantation. Arch Intern Med 1979; 139: 279.
34. Rand K, Pollard R, Merigan T. Increased pulmonary superinfections in cardiac transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978; 298 (17): 951.
35. Bailey T, Powderly W, Storch G, et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993; 21 (2): 196.
36. Boland G, Hene R, Ververs C, DeHaan M, DeGast G. Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993; 94: 306.